RxDoctor Payments Data

Aaron Kaufman, MD

Ophthalmology · Boston, MANPI 1174028096

Payments from drug & device makers

$5,122in general payments, 2019–2025

Across 40 payments — averaging $128.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Haag-streit USA, Inc.$3K
  • Alcon$693
  • Biotissue Holdings Inc.$624
  • Glaukos Corporation$339
  • Harrow Eye, LLC$145
  • Dompe US, Inc.$142
  • plus $178 from 4 others

What the payments were for

  • Consulting fees$3,00059%
  • Food & beverage$2,12241%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,122 in reported general payments places this provider in the 75th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$23,076
Medicare patients
115
Services billed
221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine48$38,246
Cyclosporine44$16,243
Prednisolone Acetate384$15,855
XiidraLifitegrast12$12,418
MoxifloxacinMoxifloxacin Hcl268$6,340
Fluorometholone63$5,190
Doxycycline Monohydrate119$3,266
Loteprednol Etabonate25$2,483
ValacyclovirValacyclovir Hcl50$1,738
ErythromycinErythromycin Base87$1,168
Brimonidine Tartrate51$1,054
Acyclovir39$987
Ketorolac Tromethamine36$768
Methazolamide11$754
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat22$472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$36$12,41812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 653 ophthalmology providers in Massachusetts.

Other ophthalmology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →